IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

∄pplicants :Susumu MUTO et al.

Group Art Unit: 1615

Appl. No.

: 10/516,294

(U.S. National Stage of PCT/JP03/07119)

I.A. Filed

: June 5, 2003

Examiner: Not Yet Assigned

MAR 0 7 200

For

: NF-KB ACTIVATION INHIBITORS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and further to the Information Disclosure Statement filed on February 24, 2006, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification and in the International Search Report of commonly assigned U.S. Application No. 10/515,623. The following is a list of additional documents cited in the above noted documents:

U.S. Patent No. 3,331,874;

G.B. Patent No. 996,074;

MATSUZAKI, et al., "Amer. J. Reproductive Immunol.," 1986, Vol. 40, page 291-294;

UCHIDE, et al., "Nikkei Medical," 2002, No. 415, page 28, with English translation;

UCHIDE, et al., "Fertility and Sterility," 2002, Vol. 78, No. 4, page 782-786; and

CHEGINI, "Frontiers in Bioscience," 2002, Vol. 7, page e91-115.

Further to 37 C.F.R. §1.98, a copy of the U.S. patent is not enclosed. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.

Applicants respectfully request that the Examiner consider the above material and cite the same. Copies of the above-noted documents and articles are attached hereto and all of the documents are listed on the attached PTO-1449 Form. The Examiner is requested to initial the appropriate spaces on the attached Form and to return a copy of the initialed Form to Applicants with the next official communication in the present application.

Applicants note that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure consideration of the submitted material. However, if any fee is necessary for consideration of this Information Disclosure Statement, the undersigned hereby authorizes the charging of any fee necessary for the consideration of this statement, including any payment under 37 C.F.R. §1.17 (p), to Deposit Account No. 19-0089.

P26316.A03.doc

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted, Susumu MUTO et al.

Bruce H. Bernstein Reg. No. 29,027

March 7, 2006 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191

Arnold Turk Reg. No. 33094

P26316.P08.docFORM PTO-1449									rtment of C		Atty. Docke			Application No. 10/516,294			
IMPORMATION DISCLOSURE STATEMENT BY APPLICANT											Applicant Susumu MUTO et al.						
\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\					eet	ets ir necessary)					Filing Date June 5, 2003			Group 1615			
TRADEMARK OF TRADEMARK									U.S. PATE	NT DOCUM	ENTS						
EXAMINER INITIAL	DOCUMENT NUMBER								DATE		NAME			BCLASS	FILING DATE IF APPROPRIATE		
	3 3 3 1 8 7 4						7	4	07/18/67	HERBE	RT C. STECKER						
															- 100		
				_													
i i										1			l				

FOREIGN PATENT DOCUMENTS

		DOC	CUME	ENT	NUM	BER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
·		9	9	6	0	7	4	06/23/65	GERMANY			_		
						·								

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
 1	MATSUZAKI, et al., "Amer. J. Reproductive Immunol.," 1986, Vol. 40, page 291-294.	
 2	UCHIIDE, et al., "Nikkei Medical," 2002, No. 415, page 28, with English translation.	
 3	UCHIIDE, et al., "Fertility and Sterility," 2002, Vol. 78, No. 4, page 782-786.	
4	CHEGINI, "Frontiers in Bioscience," 2002, Vol. 7, page e91-115.	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.